{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:38:07Z","timestamp":1771015087338,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","valueinhealthjournal.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.jval.2015.12.018","type":"journal-article","created":{"date-parts":[[2016,3,5]],"date-time":"2016-03-05T18:19:28Z","timestamp":1457201968000},"page":"374-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy"],"prefix":"10.1016","volume":"19","author":[{"given":"Ursula","family":"Becker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago G.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua A.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Samanta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2015.12.018_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.23491","article-title":"Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment","volume":"88","author":"Hallek","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jval.2015.12.018_bib2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2407-9-252","article-title":"The incidence of and mortality from leukaemias in the UK: a general population-based study","volume":"9","author":"Bhayat","year":"2009","journal-title":"BMC Cancer"},{"issue":"Suppl. 6","key":"10.1016\/j.jval.2015.12.018_bib3","doi-asserted-by":"crossref","first-page":"vi50","DOI":"10.1093\/annonc\/mdr377","article-title":"Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Eichhorst","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2015.12.018_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO Guidelines consensus conference on malignant lymphoma 2011, part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2015.12.018_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2013.1.158","article-title":"Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers","volume":"2013","author":"Shanafelt","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jval.2015.12.018_bib7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/CCO.0000000000000107","article-title":"Obinutuzumab: a new class of anti-CD20 monoclonal antibody","volume":"26","author":"Gagez","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.jval.2015.12.018_bib8","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2015.12.018_bib9","unstructured":"National Institute for Health and Care Excellence. Appraisal guidance document: obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. June 2015. Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ta343\/resources\/guidance-obinutuzumab-in-combination-with-chlorambucil-for-untreated-chronic-lymphocytic-leukaemia-pdf\u3009. [Accessed October 1, 2015]."},{"key":"10.1016\/j.jval.2015.12.018_bib10","unstructured":"National Institute for Health and Care Excellence. Appraisal guidance document: ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia. June 2015. Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ta344\u3009. [Accessed October 1, 2015]."},{"key":"10.1016\/j.jval.2015.12.018_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2011.41.5646","article-title":"Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies","volume":"31","author":"Woyach","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jval.2015.12.018_bib12","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3111\/13696990701571585","article-title":"Cost effectiveness of oral fludarabine in chronic lymphocytic leukaemia: the French case","volume":"10","author":"Dervaux","year":"2007","journal-title":"J Med Econ"},{"key":"10.1016\/j.jval.2015.12.018_bib13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2165\/00044011-200727110-00002","article-title":"Economic evaluation of third-line treatment with alemtuzumab for chronic lymphocytic leukaemia","volume":"27","author":"Scott","year":"2007","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jval.2015.12.018_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/10428194.2011.605918","article-title":"Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia","volume":"53","author":"Hornberger","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2015.12.018_bib15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1876824501204010018","article-title":"Economic analysis of alemtuzumab (MabCampath\u00ae) in fludarabine-refractory chronic lymphocytic leukemia","volume":"4","author":"Mittmann","year":"2012","journal-title":"Open Pharmacoecon Health Econ J"},{"key":"10.1016\/j.jval.2015.12.018_bib16","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jval.2015.12.018_bib17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2015.12.018_bib18","first-page":"120","author":"Fischer","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jval.2015.12.018_bib19","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jval.2015.12.018_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10198-010-0233-7","article-title":"Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences","volume":"11","author":"Crott","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2015.12.018_bib21","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/JTO.0b013e3181f77a6a","article-title":"Derivation of utility values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 questionnaire values in lung cancer","volume":"5","author":"Jang","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jval.2015.12.018_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1477-7525-10-151","article-title":"Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients","volume":"10","author":"Kim","year":"2012","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2015.12.018_bib23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/0272989X11427761","article-title":"Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D","volume":"32","author":"Versteegh","year":"2012","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2015.12.018_bib24","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3109\/10428194.2014.961012","article-title":"Health state utilities for chronic lymphocytic leukemia: importance of prolonging progression free survival","volume":"56","author":"Kosmas","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2015.12.018_bib25","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2008"},{"key":"10.1016\/j.jval.2015.12.018_bib26","unstructured":"National Institute for Health and Care Excellence. Appraisal consultation document: obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia. November 2014. Available from: \u3008http:\/\/www.nice.org.uk\/guidance\/gid-tag451\/documents\/leukaemia-chronic-lymphocytic-obinutuzumab-with-chlorambucil-1st-line-id650-appraisal-consultation-document-22\u3009. [Accessed November 2, 2014]."},{"key":"10.1016\/j.jval.2015.12.018_bib27","series-title":"British National Formulary (BNF) 66, 9 September 2013","year":"2013"},{"key":"10.1016\/j.jval.2015.12.018_bib28","unstructured":"Department of Health, UK. Policy paper: NHS reference costs 2012 to 2013. Available from: \u3008https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2012-to-2013\u3009. [Accessed April 1, 2013]."},{"key":"10.1016\/j.jval.2015.12.018_bib29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/0272989X9401400308","article-title":"Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment","volume":"14","author":"Cantor","year":"1994","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2015.12.018_bib30","first-page":"122","article-title":"Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911)","author":"Hillmen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jval.2015.12.018_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s40273-014-0187-1","article-title":"Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility","volume":"32","author":"Marsh","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2015.12.018_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterein","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jval.2015.12.018_bib33","doi-asserted-by":"crossref","first-page":"A485","DOI":"10.1016\/S1098-3015(10)66616-8","article-title":"Health state preference study mapping the change over the course of the disease process in chronic lymphocytic leukaemia (CLL)","volume":"11","author":"Ferguson","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2015.12.018_bib34","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/S0959-8049(01)00307-0","article-title":"Quality of life measurement in oncology\u2014a matter of the assessment instrument?","volume":"37","author":"Holzner","year":"2001","journal-title":"Eur J Cancer"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301516000036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301516000036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T18:13:59Z","timestamp":1600280039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301516000036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1098301516000036"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2015.12.018","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2015.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by International Society for Pharmacoeconomics and Outcomes Research (ISPOR)","name":"copyright","label":"Copyright"}]}}